Do you offer adjuvant pembrolizumab post metachronous oligometastatic resection of RCC beyond the first year of diagnosis?  

For patients with recurrence beyond 1 year of initial nephrectomy, I would not offer post metastasectomy pembrolizumab. Such patients would usually belong to the IMDC favorable risk category at the time of recurrence and could have a continued disease free interval post metastasectomy based on sever...